View Older Stories View More Recent Stories

Jun 6, 2022 04:01PM Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
Jun 3, 2022 05:12PM Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 1, 2022 06:00AM Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 31, 2022 07:30AM DTx Pharma Appoints Michael Huang, MD as Chief Medical Officer
May 25, 2022 05:14PM Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 25, 2022 04:31PM Form SC 13G Celcuity Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 25, 2022 10:00AM Adela Initiates Key Study for Cancer Early Detection Program
May 23, 2022 10:00AM Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board
May 20, 2022 04:31PM Form SC 13D PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 19, 2022 06:30AM Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines
May 16, 2022 06:18PM Form SC 13G/A Bolt Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 16, 2022 05:51PM Form SC 13G/A Olema Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 16, 2022 05:04PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
May 16, 2022 05:03PM Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 16, 2022 04:52PM Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 16, 2022 04:00PM Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022 08:00AM Avilar Therapeutics Announces Formation of Scientific Advisory Board With Leading Experts in Protein Degradation, Chemistry, Genetics, and Drug Discovery
May 16, 2022 07:03AM Celcuity (CELC) Announces $100M Private Placement
May 16, 2022 07:00AM Celcuity Inc. Announces $100 Million Private Placement
May 4, 2022 08:08AM Achilles Therapeutics (ACHL) Appoints Bernhard Ehmer to its Board
May 4, 2022 08:00AM Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
May 4, 2022 08:00AM Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
May 3, 2022 08:00AM Avilar Therapeutics Executives to be Featured Speakers on Advances in Protein Degradation at Upcoming Drug Discovery Conferences
May 3, 2022 03:00AM Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
May 2, 2022 04:31PM Form SC 13D/A Nkarta, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 2, 2022 10:00AM Scribe Therapeutics Expands Collaboration With Biogen to Second Target
May 2, 2022 07:30AM DTx Pharma Announces Appointment of Kathie M. Bishop to its Board of Directors
Apr 28, 2022 05:01PM Form SC 13G NanoString Technologies Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 25, 2022 04:31PM Form SC 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 21, 2022 04:31PM Form SC 13G VERU INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 19, 2022 08:00AM Avilar Therapeutics to Present Scientific Poster on ATACs, a New Class of Degraders for Targeting Extracellular Proteins, at Protein Degradation Conference
Apr 14, 2022 06:30AM Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
Apr 13, 2022 06:00AM CDR-Life Announces $76 Million Raised in Series A Funding
Apr 13, 2022 06:00AM Jeito Capital Co-Leads $76 Million Series A Financing for CDR-Life, its 10th Investment Since its Launch
Apr 11, 2022 04:43AM Adcendo presents Data on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
Apr 8, 2022 04:33PM Form SC 13G AN2 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 6, 2022 09:00AM  TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
Apr 6, 2022 08:00AM PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Apr 5, 2022 08:00AM PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
Apr 1, 2022 04:32PM Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 1, 2022 10:00AM Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
Apr 1, 2022 06:00AM RA Capital Management Pivots to Metaverse Medicines
Mar 31, 2022 07:30AM Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Mar 31, 2022 07:30AM Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Mar 30, 2022 08:00AM PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
Mar 24, 2022 04:33PM Form SC 13G FLUIDIGM CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 23, 2022 08:30AM Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer
Mar 15, 2022 08:00AM PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
Mar 14, 2022 05:05PM Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 14, 2022 08:00AM Avilar Therapeutics to Present at the Guggenheim Targeted Protein Degrader Day
View More Recent Stories View Older Stories